Turn Therapeutics' GX-03 Interim Phase 2 Data Shows 92.6% EASI-50, Strong Safety in Eczema Trial
TTRX has more than doubled off its 52-week low of $2.57 on elevated volume (4.8× avg).
Summary
Turn Therapeutics announced highly positive interim Phase 2 results for its lead atopic dermatitis candidate, GX-03. The trial demonstrated rapid and deep efficacy, with 92.6% of patients achieving EASI-50 at 4 weeks and 70.4% achieving EASI-75, alongside a favorable safety profile with no serious adverse events. This news follows an 8-K filed earlier today and builds on positive preclinical data for GX-03 announced last week. These strong efficacy and safety results significantly de-risk the drug's development, which is critical for a small-cap biotech company that previously disclosed substantial doubt about its ability to continue as a going concern. The company will present detailed findings at the Jefferies Global Healthcare conference on June 4, 2026, and plans to engage the FDA on its regulatory strategy.
At the time of this announcement, TTRX was trading at $5.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $154.9M. The 52-week trading range was $2.57 to $26.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.